We’re pleased to recognize gifted and passionate individuals like Ibs Mahmood who consistently find and create new ways to disrupt the healthcare industry to improve patients’ lives.
KING OF PRUSSIA, PA and LONDON, UK (PRWEB) June 04, 2015
DrugDev President and CEO Ibraheem (Ibs) Mahmood continues to gain recognition for disrupting the status quo in the healthcare industry. PM360, a leading health-marketing industry trade magazine, voted Ibs among only six executives worldwide as a winner in the “Disrupter” category in its inaugural ELITE award program. Over the past year Ibs was featured in a CenterWatch “Insider Insights” executive profile, named to the PharmaVOICE 100 most inspiring people in the life sciences industries, and was a finalist for the SCRIP Executive of the Year award.
The ELITE awards by PM360 profile the most influential people in the healthcare industry.
Nominees were evaluated based on their accomplishments, testimonials from clients and colleagues, and supporting evidence that reflects the impact of their efforts. Winners were selected from among hundreds of nominations.
Anna Stashower, CEO and Publisher of PM360, said, “We’re pleased to recognize gifted and passionate individuals like Ibs Mahmood who consistently find and create new ways to disrupt the healthcare industry to improve patients’ lives.”
Other PM360 ELITE winners include Brenton “Brent” Saunders, the CEO of Actavis; Frank Segrave, President & CEO, Silvergate Pharmaceuticals, Inc.; Hugh O’Neill, President, Commercial Operations NA, Mallinckrodt, and others. ELITE winners are profiled in PM360’s May issue and will be honored at a celebratory cocktail party in New York City this July.
Ibs Mahmood said, “I’m honored to be included among such a remarkable group of people who are dedicated to achieving change in the healthcare industry. It’s no secret that disruption is needed to fundamentally change the way our industry conducts clinical trials so we can get more drugs to patients faster. I share this award with my colleagues at DrugDev and our innovative customers who have committed to stop talking about change, and do it.”
Visit DrugDev at the DIA Annual Meeting in Washington DC, June 14-18, Booth #820.
DrugDev is an innovative technology company which provides cloud-based solutions to help sponsors, CROs and investigators do more clinical trials together. Built around the largest global network of active opted-in investigators, DrugDev’s unified solutions suite optimizes site selection and startup, investigator payments and clinical operations. DrugDev also serves as the trusted third-party host of the revolutionary Investigator Databank collaboration. Learn why 9 of the top 10 sponsors and 4 of the top 5 CROs rely on DrugDev technology to do more trials at drugdev.com.